New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

Stock Information for Nuwellis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nuwellis Inc.

Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy
Nuwellis Regains Compliance with Nasdaq Listing Requirements
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid
Nuwellis Announces Preliminary Results for Third Quarter of 2024
Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.